Extended-release oxybuytynin and tolterodine treat overactive bladder

Affiliations

Comment

Adrienne Z Ables. J Fam Pract. 2003 Nov.

. 2003 Nov;52(11):829-30.

¹ Spartanburg Family Medicine Residency Program, Spartanburg, SC, USA. aables@srhs.com

No abstract available

Comment on

Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.
Diokno AC, Appell RA, Sand PK, Dmochowski RR, Gburek BM, Klimberg IW, Kell SH; OPERA Study Group. Diokno AC, et al. Mayo Clin Proc. 2003 Jun;78(6):687-95. doi: 10.4065/78.6.687. Mayo Clin Proc. 2003. PMID: 12934777 Clinical Trial.